Small structural changes of the imidazopyridine diacylglycerol acyltransferase 2 (DGAT2) inhibitors produce an improved safety profile

• DOI: 10.1039/c6md00564k
• Publication Date: 2016-11-22T09:24:13Z
• Authors: K. Futatsugi; K. Huard; D. W. Kung; J. C. Pettersen; D. A. Flynn; J. R. Gosset; G. E. Aspnes; R. J. Barnes; S. Cabral; M. S. Dowling; D. P. Fernando; T. C. Goosen; W. P. Gorczyca; D. Hepworth; M. Herr; S. Lavergne; Q. Li; M. Niosi; S. T. M. Orr; I. D. Pardo; S. M. Perez; J. Purkal; T. J. Schmahai; N. Shirai; A. M. Shoieb; J. Zhou; B. Goodwin
• Keywords: 0303 health sciences; 03 medical and health sciences; 3. Good health

Preclinical pharmacokinetic, efficacy, and toxicology results are reported for a series of DGAT2 inhibitors for the potential treatment of hypertriglyceridemia.